@the_news_21
Drugs Controller General of India has given approval to drug which is developed by DRDO. This anti-COVID-19 medication can be used as adjunct therapy in moderate to severe patients. According to the Defence Ministry, the 2-deoxy-D-glucose (2-DG) drug was developed in collaboration with Hyderabad-based Dr Reddy’s Laboratories.
According to officials, the 2-DG drug had been shown to help ensure faster recovery of hospitalised patients as well as reducing supplemental oxygen dependence during clinical trials. The drug accumulates in infected cells, preventing virus growth by stopping viral synthesis and energy production. The Defence Ministry contends that its selective accumulation in virally-infected cells makes this drug unique.